18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With TEAEs, TESAEs and Drug-related TEAEs and TESAEsPrimary· Approximately 3 years (from first study treatment until safety follow-up)
Treatment emergent adverse events (TEAEs) were defined as AEs starting or worsening during the treatment period. The treatment period extended from the first date of study treatment in this study until the safety follow-up (30 days after the last administration of study treatment). TESAEs: Treatment emergent serious adverse events.
Any TEAE
Group
Value
95% CI
Anetumab Ravtansine
9
Serious TEAE
Group
Value
95% CI
Anetumab Ravtansine
2
Any study drug-related TEAE
Group
Value
95% CI
Anetumab Ravtansine
8
Any study drug-related Serious TEAE
Group
Value
95% CI
Anetumab Ravtansine
0
Overall SurvivalSecondary· Approximately 3 years (from first study treatment until safety follow-up)
Overall survival (OS) defined as the time from first treatment in this study until death from any cause. Data on survival were collected by the site. Time frame was reduced due to early termination of the study. Table reports Kaplan-Meier median with Brookmeyer-Crowley confidence intervals. Number (%) of participants with event: 5 (55.6%) and Number (%) of participants censored: 4 (44.4%).
25th percentile
Group
Value
95% CI
Anetumab Ravtansine
17.6
6.9 – 34.1
Median
Group
Value
95% CI
Anetumab Ravtansine
34.1
6.9 – NA
75th percentile
Group
Value
95% CI
Anetumab Ravtansine
NA
28.5 – NA
Adverse events — posted to ClinicalTrials.gov
Time frame: For TEAE: After the first study intervention up to 30 days after the end of study intervention, approximately 3 years. For the all-cause mortality: considering all deaths that occurred at any time during the study before the last contact, up to approximately 3 years..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. The patients will be observed to collect information on how safe and efficient the drug is.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
· recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors
· Phase 1
· recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre
· Phase 3
· recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe
· Phase 1
· recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
· EARLY_PHASE1
· recruiting
Other Bayer trials
Trials by the same sponsor.
NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis
· not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt
· not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About
· not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child
· Phase 3
· not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03926143.